JP7832927B2 - Crf2受容体アゴニスト及び治療におけるその使用 - Google Patents

Crf2受容体アゴニスト及び治療におけるその使用

Info

Publication number
JP7832927B2
JP7832927B2 JP2023512076A JP2023512076A JP7832927B2 JP 7832927 B2 JP7832927 B2 JP 7832927B2 JP 2023512076 A JP2023512076 A JP 2023512076A JP 2023512076 A JP2023512076 A JP 2023512076A JP 7832927 B2 JP7832927 B2 JP 7832927B2
Authority
JP
Japan
Prior art keywords
gglu
peptide
fmoc
resin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023512076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541798A (ja
JP2023541798A5 (cg-RX-API-DMAC10.html
Inventor
イリヤーノ,ステファン
ルーカス,ローレンス
レテイン,レティシア
ボーヴェルジェ,フィリップ
ヤニアック,フィリップ
オズー,マリー-ローレ
ハッランド,ニス
リ,ジユウ
エルベルト,ラルフ
エヴァース,アンドレアス
ビアンキ,エリザベッタ
サントプレーテ,アレッシア
ロヴェルシ,ダニエラ
トリッペピ,マルティナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2023541798A publication Critical patent/JP2023541798A/ja
Publication of JP2023541798A5 publication Critical patent/JP2023541798A5/ja
Priority to JP2026007364A priority Critical patent/JP2026071260A/ja
Application granted granted Critical
Publication of JP7832927B2 publication Critical patent/JP7832927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023512076A 2020-08-19 2021-08-18 Crf2受容体アゴニスト及び治療におけるその使用 Active JP7832927B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026007364A JP2026071260A (ja) 2020-08-19 2026-01-20 Crf2受容体アゴニスト及び治療におけるその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20315387 2020-08-19
EP20315387.9 2020-08-19
PCT/EP2021/072923 WO2022038179A1 (en) 2020-08-19 2021-08-18 Crf2 receptor agonists and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026007364A Division JP2026071260A (ja) 2020-08-19 2026-01-20 Crf2受容体アゴニスト及び治療におけるその使用

Publications (3)

Publication Number Publication Date
JP2023541798A JP2023541798A (ja) 2023-10-04
JP2023541798A5 JP2023541798A5 (cg-RX-API-DMAC10.html) 2025-09-24
JP7832927B2 true JP7832927B2 (ja) 2026-03-18

Family

ID=72615799

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023512076A Active JP7832927B2 (ja) 2020-08-19 2021-08-18 Crf2受容体アゴニスト及び治療におけるその使用
JP2026007364A Pending JP2026071260A (ja) 2020-08-19 2026-01-20 Crf2受容体アゴニスト及び治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026007364A Pending JP2026071260A (ja) 2020-08-19 2026-01-20 Crf2受容体アゴニスト及び治療におけるその使用

Country Status (16)

Country Link
US (1) US12679878B2 (cg-RX-API-DMAC10.html)
EP (2) EP4199946B1 (cg-RX-API-DMAC10.html)
JP (2) JP7832927B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230051583A (cg-RX-API-DMAC10.html)
CN (1) CN116472053B (cg-RX-API-DMAC10.html)
AU (1) AU2021328673A1 (cg-RX-API-DMAC10.html)
CA (1) CA3192032A1 (cg-RX-API-DMAC10.html)
ES (1) ES2988026T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240906T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066991T2 (cg-RX-API-DMAC10.html)
IL (1) IL300464B1 (cg-RX-API-DMAC10.html)
IS (1) IS3063B (cg-RX-API-DMAC10.html)
MX (1) MX2023002087A (cg-RX-API-DMAC10.html)
PL (1) PL4199946T3 (cg-RX-API-DMAC10.html)
WO (1) WO2022038179A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202301784B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy
KR20260089954A (ko) 2023-11-17 2026-06-16 구브라 에이/에스 hCRHR2 선택적 폴리펩타이드
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體2(crfr2)促效劑
WO2025230248A1 (ko) * 2024-04-30 2025-11-06 한미약품 주식회사 Crf2 수용체 작용제와 그 아실화 결합체의 용도
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026139062A1 (zh) * 2024-12-26 2026-07-02 杭州先为达生物科技股份有限公司 促肾上腺皮质激素释放因子2受体激动剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2018013803A1 (en) 2016-07-15 2018-01-18 Eli Lilly And Company Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN104356224A (zh) 2014-10-24 2015-02-18 杭州阿德莱诺泰制药技术有限公司 一种制备萨摩鲁泰的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2018013803A1 (en) 2016-07-15 2018-01-18 Eli Lilly And Company Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy

Also Published As

Publication number Publication date
ZA202301784B (en) 2024-01-31
JP2023541798A (ja) 2023-10-04
MX2023002087A (es) 2023-03-23
EP4435001A3 (en) 2024-10-09
IL300464A (en) 2023-04-01
HRP20240906T1 (hr) 2024-10-11
EP4199946C0 (en) 2024-06-05
IS3063B (is) 2025-06-15
CA3192032A1 (en) 2022-02-24
WO2022038179A1 (en) 2022-02-24
JP2026071260A (ja) 2026-04-28
PL4199946T3 (pl) 2024-08-19
HUE066991T2 (hu) 2024-09-28
US20250243255A1 (en) 2025-07-31
EP4435001A2 (en) 2024-09-25
CN116472053A (zh) 2023-07-21
IL300464B1 (en) 2026-07-01
CN116472053B (zh) 2026-07-31
EP4199946B1 (en) 2024-06-05
ES2988026T3 (es) 2024-11-19
US12679878B2 (en) 2026-07-14
EP4199946A1 (en) 2023-06-28
KR20230051583A (ko) 2023-04-18
AU2021328673A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
JP2026071260A (ja) Crf2受容体アゴニスト及び治療におけるその使用
CN111491658B (zh) 肠促胰岛素类似物及其用途
CA3084004C (en) Incretin analogs and uses thereof
JP7450724B2 (ja) インクレチン類似体およびその使用
JP2023078367A (ja) 新規glp-1類似体
TWI763972B (zh) 經修飾之脂質化鬆弛素b鏈胜肽及其醫療用途
KR20120123443A (ko) 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트
KR102886870B1 (ko) 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
JP7350851B2 (ja) グルカゴン由来ペプチド及びその用途
JP2025525218A (ja) インクレチンアナログおよびその使用
JP2017510636A (ja) 新規なエキセナチド類似体及びその用途
AU2024215381A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2019140030A1 (en) Combination therapy
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40087027B (en) Crf2 receptor agonists and their use in therapy
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40112064A (en) Crf2 receptor agonists and their use in therapy
HK40095414A (en) Crf2 receptor agonists and their use in therapy
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7832927

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150